{"id":2046,"date":"2017-10-27T10:13:45","date_gmt":"2017-10-27T14:13:45","guid":{"rendered":"https:\/\/www.bumc.bu.edu\/compbiomed\/?p=2046"},"modified":"2017-10-27T10:13:45","modified_gmt":"2017-10-27T14:13:45","slug":"boston-researchers-to-head-16-6-million-effort-to-intercept-cancer","status":"publish","type":"post","link":"https:\/\/www.bumc.bu.edu\/compbiomed\/2017\/10\/27\/boston-researchers-to-head-16-6-million-effort-to-intercept-cancer\/","title":{"rendered":"Boston researchers to head $16.6 million effort to \u2018intercept\u2019 cancer"},"content":{"rendered":"<p>Thursday,\u00a0October 26,\u00a02017<br \/>\nWritten by:\u00a0Sophia Eppolito\u00a0| Source: <a href=\"http:\/\/www.bostonglobe.com\/business\/2017\/10\/25\/boston-researchers-head-million-effort-intercept-cancer\/CvTdXO1RoEEd54WjEaVLuO\/story.html?camp=bg%3Abrief%3Arss%3Afeedly&amp;rss_id=feedly_rss_brief&amp;s_campaign=bostonglobe%3Asocialflow%3Atwitter\">Boston Globe<\/a><\/p>\n<p>The nonprofit Stand Up To Cancer is launching a $16.6 million program to investigate new ways of halting lung and pancreatic cancers in the early stages, and Boston scientists will head up three of the four research teams.<\/p>\n<p>The group, which is announcing the program Thursday, said that <a href=\"http:\/\/profiles.bu.edu\/Avrum.Spira\">Dr. Avrum Spira<\/a>, director of the Boston University \u2013 Boston Medical Center Cancer Center, will oversee the lung cancer interception \u201cDream Team\u201d; Dr. Lecia Sequist, director of the Center for Innovation in Early Cancer Detection at Massachusetts General Hospital, will head a team focused on lung cancer translational research; and Dr. David P. Ryan, chief of Mass. General\u2019s division of hematology and oncology, will lead the pancreatic cancer team.<\/p>\n<p id=\"U834141026855dD\">Lung cancer is the leading cause of cancer death and is expected to cause 156,000 deaths in 2017, according to the National Cancer Institute. Although pancreatic cancer accounts for only 3 percent of all diagnosed cancers, it causes 7 percent of all cancer deaths.<\/p>\n<p>These cancers are often detected when the tumors are already inoperable. Stand Up To Cancer, which raises funds to get new therapies to patients quickly, will focus on developing non-invasive tests for early tumor detection and interception.<\/p>\n<p>\u201cCan we identify the earliest molecular events that lead to lung cancer, find something we can measure in the blood, the urine, and then find a way to prevent that from becoming invasive?\u201d BU\u2019s Spira asked.<\/p>\n<p>Spira said he hopes that this program will revolutionize cancer diagnosis. \u201cIt\u2019s a transformative era in cancer research in general and lung cancer specifically,\u201d he said. \u201cWe\u2019re moving towards intercepting the disease and preventing it from happening in the first place and to me that\u2019s the future of cancer research.\u201d<\/p>\n<p>Sequist\u2019s team will receive a grant of $2 million for one year. The other three teams will receive grants of between $2.6 million and $7 million for four years.<\/p>\n<p>Stand up to Cancer is a division of the Entertainment Industry Foundation.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Thursday,\u00a0October 26,\u00a02017 Written by:\u00a0Sophia Eppolito\u00a0| Source: Boston Globe The nonprofit Stand Up To Cancer is launching a $16.6 million program to investigate new ways of halting lung and pancreatic cancers in the early stages, and Boston scientists will head up three of the four research teams. The group, which is announcing the program Thursday, said [&hellip;]<\/p>\n","protected":false},"author":11679,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[10,4,11,7],"tags":[],"_links":{"self":[{"href":"https:\/\/www.bumc.bu.edu\/compbiomed\/wp-json\/wp\/v2\/posts\/2046"}],"collection":[{"href":"https:\/\/www.bumc.bu.edu\/compbiomed\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bumc.bu.edu\/compbiomed\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/compbiomed\/wp-json\/wp\/v2\/users\/11679"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/compbiomed\/wp-json\/wp\/v2\/comments?post=2046"}],"version-history":[{"count":1,"href":"https:\/\/www.bumc.bu.edu\/compbiomed\/wp-json\/wp\/v2\/posts\/2046\/revisions"}],"predecessor-version":[{"id":2047,"href":"https:\/\/www.bumc.bu.edu\/compbiomed\/wp-json\/wp\/v2\/posts\/2046\/revisions\/2047"}],"wp:attachment":[{"href":"https:\/\/www.bumc.bu.edu\/compbiomed\/wp-json\/wp\/v2\/media?parent=2046"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/compbiomed\/wp-json\/wp\/v2\/categories?post=2046"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/compbiomed\/wp-json\/wp\/v2\/tags?post=2046"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}